Monobodies with potent neutralizing activity against SARS-CoV-2 Delta and other variants of concern

Taishi Kondo, Kazuhiro Matsuoka, Shun Umemoto, Tomoshige Fujino, Gosuke Hayashi, Yasumasa Iwatani, and Hiroshi Murakami

DOI: https://doi.org/10.26508/lsa.202101322

Corresponding author(s): Hiroshi Murakami, Nagoya University

Review Timeline:

| Event                  | Date         |
|------------------------|--------------|
| Submission Date        | 2021-11-28   |
| Editorial Decision     | 2022-01-11   |
| Revision Received      | 2022-01-20   |
| Editorial Decision     | 2022-02-11   |
| Revision Received      | 2022-02-17   |
| Accepted               | 2022-02-18   |

Scientific Editor: Novella Guidi

Transaction Report:

(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.)
January 11, 2022

Re: Life Science Alliance manuscript #LSA-2021-01322-T

Dr. Hiroshi Murakami  
Nagoya University  
Department of Biomolecular Engineering, Graduate School of Engineering  
Furo-cho  
Chikusa-ku  
Nagoya, Aichi 464-8603  
Japan

Dear Dr. Murakami,

Thank you for submitting your manuscript entitled "Monobodies with potent neutralizing activity against SARS-CoV-2 delta and other variants of concern" to Life Science Alliance. The manuscript was assessed by expert reviewers, whose comments are appended to this letter. We, thus, encourage you to submit a revised version of the manuscript back to LSA that responds to all of the reviewers’ points.

To upload the revised version of your manuscript, please log in to your account: https://lsa.msubmit.net/cgi-bin/main.plex

You will be guided to complete the submission of your revised manuscript and to fill in all necessary information. Please get in touch in case you do not know or remember your login name.

While you are revising your manuscript, please also attend to the below editorial points to help expedite the publication of your manuscript. Please direct any editorial questions to the journal office.

The typical timeframe for revisions is three months. Please note that papers are generally considered through only one revision cycle, so strong support from the referees on the revised version is needed for acceptance.

When submitting the revision, please include a letter addressing the reviewers’ comments point by point.

We hope that the comments below will prove constructive as your work progresses.

Thank you for this interesting contribution to Life Science Alliance. We are looking forward to receiving your revised manuscript.

Sincerely,

Novella Guidi, PhD  
Scientific Editor  
Life Science Alliance

---------------------------------------------------------------------------

A. THESE ITEMS ARE REQUIRED FOR REVISIONS

-- A letter addressing the reviewers' comments point by point.

-- An editable version of the final text (.DOC or .DOCX) is needed for copyediting (no PDFs).

-- High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, https://www.life-science-alliance.org/authors

-- Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title and running title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.

-- By submitting a revision, you attest that you are aware of our payment policies found here: https://www.life-science-alliance.org/copyright-license-fee
B. MANUSCRIPT ORGANIZATION AND FORMATTING:

Full guidelines are available on our Instructions for Authors page, https://www.life-science-alliance.org/authors

We encourage our authors to provide original source data, particularly uncropped/-processed electrophoretic blots and spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excel-file per figure for this information. These files will be linked online as supplementary "Source Data" files.

***IMPORTANT: It is Life Science Alliance policy that if requested, original data images must be made available. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original microscopy and blot data images before submitting your revision.***

Reviewer #1 (Comments to the Authors (Required)):

Kondo et al. report affinity maturation of the SARS-CoV-2 spike-binding monobodies developed by the authors previously and neutralization activities of these optimized monobodies against wild-type SARS-CoV-2 and the recent variants of concern. This is a topic of high general interest. The very high RBD-binding affinities and neutralizing activities of the optimized monobodies (C4-AM2 and C12b-AM2 have KD < 0.01 nM) are impressive, making them useful reagents with possible diagnostic or therapeutic potentials. The data shown are of high quality and the presentation is clear and easy to follow.

I have questions regarding selectivity of monobodies in general. Please see comments below on this and other points.

Why is C12b-AM2 not included in the analyses presented in Figs. 3, 4?

How selective are these monobodies, the C6b and C12b series in particular? Could the authors test binding to a negative control protein (something other than RBD) in BLI?

The mixed bases notation (N = A, C, G, T ; K = G or T) should be defined.

"We found that the extension of the natural sequence at the C-terminal improved the monobody solubility (data not shown)." This point should be elaborated. "C-terminal" should be C-terminus.

Undetectable koff  Undetectable dissociation or unmeasurable koff

KD was not detected  KD was not determined

In Table 1, what do (DR) and (TS) represent?

"Since the KD values observed against the RBDs of these variants were 1.7 to 6.3 nM, the IC50 values were 10 times higher than we expected. The monobody C4-AM2 might have fast and slow dissociation rates (Fig. 3 and S4), and the slow dissociation rate contributed to the low IC50 values."

The slow dissociation contributes to high affinity (small KD). It does not explain the much lower IC50 compared to KD. Is it possible that virus neutralization is not simply due to RBD-binding?

"C4-AM2 might have fast and slow dissociation rates"  fast association and slow dissociation?

"10 times higher” lower

Reviewer #2 (Comments to the Authors (Required)):

This manuscript describes the use of the mRNA-based TRAP display system to affinity mature the original monobodies previously discovered against the COVID-19 virus Receptor Binding Domain (RBD). The residues in the BC and FG loops were made into saturated combinatorial libraries from which the most frequently found clones by the next generation sequencing techniques were identified for the next round of affinity maturation campaign. The resulting monobody variants had up to almost 100-fold increase in affinity against the RBD. The affinity matured monobodies also showed increased affinity towards 4 major COVID-19 variants of concern (VOC). Importantly, the improved affinity correlated to enhanced neutralization potency against the wt and VOCs.

The manuscript was described in great technical detail, particularly the Methods section. The techniques used were state of the art and the designs of the experiments were appropriate. The conclusions, both the affinity and the neutralization potency, were strongly supported by the data presented. Overall, this manuscript appears to only present facts of the study but lacks elaboration of why it is interesting and important given that discovery, engineering and characterization of many antibodies,
especially the nanobodies isolated from the llamas that are similar in both the structure and size, have been extensively published in the past year. If the affinity maturation is the focus, saturation mutagenesis is already a standard and well-established protein engineering technique, hence obtaining improved clones, while interesting, is not too surprising. What's surprising is the finding that the monobodies in their monomeric form achieved extremely high neutralizing potency comparable to the bivalent neutralizing IgG, with EC50 values lower than their equilibrium constants (affinity). The authors are encouraged to further elaborate on these findings and speculate the possible reasons. Would the high potency the results of protein aggregation? Lastly, would the bivalent monobodies in the Fc-fusion form further enhance neutralization potency? Given the rapid clearance of small proteins such as the monobodies, this bivalent format widely used in therapeutic biologics deserves further studies.

Reviewer #3 (Comments to the Authors (Required)):

The authors have published a paper in Science Advances in October 2020 where they use an innovative selection method, termed TRAP display, to engineer high-affinity FN3-monobodies to the RBD of the spike protein of SARS-CoV2. These monobodies bound with low nanomolar affinities to the RBD, but showed only moderate virus neutralization activity. In this study, the authors used affinity maturation to increase binding affinity and neutralization activity of three different monobody clones from their previous study. The resulting monobodies have an impressive affinity in the sub-nanomolar range with significantly slower koff rates and have potent neutralizing activity (up to 100-fold better than parent monobody) against different SARS-CoV2 spike mutants. Monobody C4-AM4 was the most potent clone and showed similar activity than a validated neutralizing monoclonal antibody. The developed monobodies are among the most potent neutralizing binding proteins against SARS-CoV2 and have great promise as therapeutic or diagnostic reagents.

This is a rigorously planned and conducted study with important results that should be published without delay.

Minor points:
1. page 3: Was the improved soluble expression of monobody C4-AM1 with C-terminal extension also observed for the parental C4 monobody?
2. page 3: The authors interpret the differences of C4 affinity in their previous study (1.9 nM) vs. this study (0.96 nM) to the removal of the Nus-Tag. But are these small affinity differences really significant and not within the error margins of SPR?
3. The manuscript would benefit from proofreading to remove typos and grammatical errors.
Response to Reviews:
We are very grateful for the reviewer’s comments and suggestions, which we found very helpful. We have revised our manuscript accordingly.

Reviewer #1 comments:

- I have questions regarding selectivity of monobodies in general. Please see comments below on this and other points.

Why is C12b-AM2 not included in the analyses presented in Figs. 3, 4?
Response: In a previous paper (Science Advances, 2020, 6(42), eabd3916.), we showed that C12b did not prevent SARS-CoV-2 infection. In Figure 3, we did not include C12b-AM2 because we focused on analyzing an affinity of a neutralizing monobody. In Figure 4, we have added C12b as a negative control. We did not use the C12b-AM2 monobody because it would not have a neutralizing activity.

How selective are these monobodies, the C6b and C12b series in particular? Could the authors test binding to a negative control protein (something other than RBD) in BLI?
Response: We performed a BLI assay using a green fluorescent protein and a ubiquitin protein as negative control proteins. We observed no binding. Please see the related manuscript file.

The mixed bases notation (N = A, C, G, T; K = G or T) should be defined.
Response: Thank you for your suggestion. We have added it to the main text and the figure legends.

"We found that the extension of the natural sequence at the C-terminal improved the monobody solubility (data not shown)." This point should be elaborated. "C-terminal" should be C-terminus.
Undetectable koff è Undetectable dissociation or unmeasurable koff
KD was not detected è KD was not determined
"10 times higher" è lower
Response: Thank you for your corrections.

In Table 1, what do (DR) and (TS) represent?
Response: There is a deletion of 2 amino acids (VR) after the random sequence for these clones. We
removed the brackets and have added the following note in the caption of Table 1: “*These clones had a two amino acid (VR) deletion after the BC loop.” We have revised Figs. S3 and S4 as well.

"Since the KD values observed against the RBDs of these variants were 1.7 to 6.3 nM, the IC50 values were 10 times higher than we expected. The monobody C4-AM2 might have fast and slow dissociation rates (Fig. 3 and S4), and the slow dissociation rate contributed to the low IC50 values."
"C4-AM2 might have fast and slow dissociation rates" è fast association and slow dissociation?
Response: We would like to draw attention to the unfitted dissociation curve in Fig. 3. To make this sentence clear, we revised it to: “the C4-AM2 monobody might have two dissociation rates (Supplementary Fig. S4)”

The slow dissociation contributes to high affinity (small KD). It does not explain the much lower IC50 compared to KD. Is it possible that virus neutralization is not simply due to RBD-binding?
Response: I agree; it does not fully explain the results, especially for the Beta and Gamma variants. At the moment, we really do not have other explanations. We have revised the sentence to read, “and the slow dissociation rate might partially contribute to the low IC50 values.”

Reviewer #2 comments:

Overall, this manuscript appears to only present facts of the study but lacks elaboration of why it is interesting and important given that discovery, engineering and characterization of many antibodies, especially the nanobodies isolated from the llamas that are similar in both the structure and size, have been extensively published in the past year. If the affinity maturation is the focus, saturation mutagenesis is already a standard and well-established protein engineering technique, hence obtaining improved clones, while interesting, is not too surprising. What's surprising is the finding that the monobodies in their monomeric form achieved extremely high neutralizing potency comparable to the bivalent neutralizing IgG, with EC50 values lower than their equilibrium constants (affinity). The authors are encouraged to further elaborate on these findings and speculate the possible reasons. Would the high potency the results of protein aggregation?
Response: We think the extremely high affinity ($K_D < 0.01$ nM) of the monobody C4-AM2 and the potent neutralization activity ($IC_{50} = 46$ pM, 0.62 ng/mL) are interesting. We agree that the $IC_{50}$ values being lower than
their $K_D$ values for VOCs is also interesting. We did not observe protein aggregation of the C4-AM2 monobody in the neutralization experiment. We also tried to determine the $K_D$ values for a spike protein trimer, but it was difficult due to the high non-specific binding of the trimer to the sencer. At the moment, we do not have an answer, although we think the fraction of the slow dissociation rate might partially contribute to the low $IC_{50}$ values.

Lastly, would the bivalent monobodies in the Fc-fusion form further enhance neutralization potency? Given the rapid clearance of small proteins such as the monobodies, this bivalent format widely used in therapeutic biologics deserves further studies.

Response: We never tried the Fc-fusion because of the relatively high cost of production. Instead, we tried a tandem format in the previous work (Science Advances, 2020, 6(42), eabd3916.), but this did not improve the neutralization activity. For an in vivo animal test, we will test the Fc-fusion to reduce the clearance rate.

Reviewer #3 comments:

1. page 3: Was the improved soluble expression of monobody C4-AM1 with C-terminal extension also observed for the parental C4 monobody?

Response: Here, we mentioned our general observations of the effects of C-terminal extension of various monobodies on their solubility. To make it clearer, we have added the solubility study of monobody C4-AM2 with three types of C-termini as Fig. S1. We revised the sentence as, “During the optimization of monobody expression, we found that the extension of the natural sequence at the C-terminus improved monobody solubility (Supplementary Fig. S1; monobody C4-AM2, vide infra).

2. page 3: The authors interpret the differences of C4 affinity in their previous study (1.9 nM) vs. this study (0.96 nM) to the removal of the Nus-Tag. But are these small affinity differences really significant and not within the error margins of SPR?

Response: We agree with this comment. We removed this sentence in the revised version.

3. The manuscript would benefit from proofreading to remove typos and grammatical errors.

Response: According to the reviewer’s suggestion, we have removed typos and grammatical errors from the manuscript through proofreading.
February 11, 2022

RE: Life Science Alliance Manuscript #LSA-2021-01322-TR

Dr. Hiroshi Murakami  
Nagoya University  
Department of Biomolecular Engineering, Graduate School of Engineering  
Furo-cho  
Chikusa-ku  
Nagoya, Aichi 464-8603  
Japan

Dear Dr. Murakami,

Thank you for submitting your revised manuscript entitled “Monobodies with potent neutralizing activity against SARS-CoV-2 Delta and other variants of concern”. We would be happy to publish your paper in Life Science Alliance pending final revisions necessary to meet our formatting guidelines.

Along with points mentioned below, please tend to the following:

- please address the remaining Reviewer 1 point
- please add the Twitter handle of your host institute/organization as well as your own or/and one of the authors in our system
- please add callouts for Figures S2A-B; S3A-C and S4A-B to your main manuscript text;
- please provide a separate Data Availability section

If you are planning a press release on your work, please inform us immediately to allow informing our production team and scheduling a release date.

LSA now encourages authors to provide a 30-60 second video where the study is briefly explained. We will use these videos on social media to promote the published paper and the presenting author (for examples, see https://twitter.com/LSAjournal/timelines/1437405065917124608). Corresponding or first-authors are welcome to submit the video. Please submit only one video per manuscript. The video can be emailed to contact@life-science-alliance.org

To upload the final version of your manuscript, please log in to your account: https://lsa.msubmit.net/cgi-bin/main.plex  
You will be guided to complete the submission of your revised manuscript and to fill in all necessary information. Please get in touch in case you do not know or remember your login name.

To avoid unnecessary delays in the acceptance and publication of your paper, please read the following information carefully.

A. FINAL FILES:

These items are required for acceptance.

- An editable version of the final text (.DOC or .DOCX) is needed for copyediting (no PDFs).
- High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, https://www.life-science-alliance.org/authors
- Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.

B. MANUSCRIPT ORGANIZATION AND FORMATTING:

Full guidelines are available on our Instructions for Authors page, https://www.life-science-alliance.org/authors

We encourage our authors to provide original source data, particularly uncropped/-processed electrophoretic blots and spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excel-file per figure for this information. These files will be linked online as supplementary “Source Data” files.
**Submission of a paper that does not conform to Life Science Alliance guidelines will delay the acceptance of your manuscript.**

**It is Life Science Alliance policy that if requested, original data images must be made available to the editors. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original data images prior to final submission.**

**The license to publish form must be signed before your manuscript can be sent to production. A link to the electronic license to publish form will be sent to the corresponding author only. Please take a moment to check your funder requirements.**

**Reviews, decision letters, and point-by-point responses associated with peer-review at Life Science Alliance will be published online, alongside the manuscript. If you do want to opt out of having the reviewer reports and your point-by-point responses displayed, please let us know immediately.**

Thank you for your attention to these final processing requirements. Please revise and format the manuscript and upload materials within 7 days.

Thank you for this interesting contribution, we look forward to publishing your paper in Life Science Alliance.

Sincerely,

Novella Guidi, PhD
Scientific Editor
Life Science Alliance

Reviewer #1 (Comments to the Authors (Required)):

The authors have adequately addressed all questions/comments from the previous review. One small point is regarding the last sentence of the Results section; the BLI data for C4-AM2 are not in supplementary Fig S4.

Reviewer #2 (Comments to the Authors (Required)):

The authors have sufficiently addressed the questions I raised in their responses. I look forward to the in vivo data using the half-life enhanced molecular format, such as the Fc-fusion.

Reviewer #3 (Comments to the Authors (Required)):

The authors fully addressed all points raised in my initial review. No further comments.
February 18, 2022

RE: Life Science Alliance Manuscript #LSA-2021-01322-TRR

Dr. Hiroshi Murakami
Nagoya University
Department of Biomolecular Engineering, Graduate School of Engineering
Furo-cho
Chikusa-ku
Nagoya, Aichi 464-8603
Japan

Dear Dr. Murakami,

Thank you for submitting your Research Article entitled “Monobodies with potent neutralizing activity against SARS-CoV-2 Delta and other variants of concern”. It is a pleasure to let you know that your manuscript is now accepted for publication in Life Science Alliance. Congratulations on this interesting work.

The final published version of your manuscript will be deposited by us to PubMed Central upon online publication.

Your manuscript will now progress through copyediting and proofing. It is journal policy that authors provide original data upon request.

Reviews, decision letters, and point-by-point responses associated with peer-review at Life Science Alliance will be published online, alongside the manuscript. If you do want to opt out of having the reviewer reports and your point-by-point responses displayed, please let us know immediately.

***IMPORTANT: If you will be unreachable at any time, please provide us with the email address of an alternate author. Failure to respond to routine queries may lead to unavoidable delays in publication.***

Scheduling details will be available from our production department. You will receive proofs shortly before the publication date. Only essential corrections can be made at the proof stage so if there are any minor final changes you wish to make to the manuscript, please let the journal office know now.

DISTRIBUTION OF MATERIALS:
Authors are required to distribute freely any materials used in experiments published in Life Science Alliance. Authors are encouraged to deposit materials used in their studies to the appropriate repositories for distribution to researchers.

You can contact the journal office with any questions, contact@life-science-alliance.org

Again, congratulations on a very nice paper. I hope you found the review process to be constructive and are pleased with how the manuscript was handled editorially. We look forward to future exciting submissions from your lab.

Sincerely,

Novella Guidi, PhD
Scientific Editor
Life Science Alliance